Atorvastatin/fenofibrate

Drug Profile

Atorvastatin/fenofibrate

Alternative Names: AtorFen; LCP-AtorFen

Latest Information Update: 09 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LifeCycle Pharma
  • Developer Athena Drug Delivery Solutions; LifeCycle Pharma; Veloxis Pharmaceuticals
  • Class Antihyperlipidaemics; Butyric acids; Fluorobenzenes; Heptanoic acids; Propionates; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hyperlipidaemia

Highest Development Phases

  • No development reported Dyslipidaemias

Most Recent Events

  • 29 Dec 2011 Atorvastatin/fenofibrate is available for sublicensing as of 29 Dec 2011. http://www.athenadiagnostics.com/content/about/
  • 23 Dec 2011 Clinical trials in Dyslipidaemia in emerging markets (PO)
  • 08 Jul 2011 Suspended - Phase-II/III for Dyslipidaemia in USA (PO); Veloxis seeks partnership opportunities
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top